Prograf combination approved for kidney transplant use in the US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Astellas's immunosuppressant Prograf (tacrolimus) for use in combination with mycophenolate mofetil (MMF, Roche's CellCept) as an adjunct therapy for the prevention of rejection in kidney transplant patients.